Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Der Kommentar von petra129 wurde ignoriert. Um die Kommentare von petra129 wieder zu sehen, klicken Sie folgenden Link:
....die mixen auch was ins Getränk - super!
Cannabis Roundup: DAVIDsTEA Preps Earnings, Aurora Cannabis Tumbles
Wall Street is expecting good things from DAVIDsTEA's earnings after the closing bell, sending the stock soaring.
Dec 13, 2018 12:45 PM EST
Pot stocks have had a rocky fourth quarter, with the ETFMG Alternative Harvest ETF (MJ - Get Report) falling 25% over the past three months.
That trend continued Thursday with the largest pot ETF by net asset value falling 1.6%. Alternative Harvest has had a rough fourth quarter since reaching a year-to-date high of up 32% in September.
The industry may be suffering from the bubble that inflated earlier this year as investors overvalued many of the stocks in the sector.
The pot industry, however, got some good news after Congress passed the 2018 Farm Bill, which legalizes the cultivation and farming of hemp, which contains cannabidiol (CBD), the non-psychoactive chemical compound found in cannabis.
Shares of New Age Beverages Corp. (NBEV - Get Report) , which manufactures CBD-infused drinks, jumped more than 11% on the news before pairing all of its gains amid a market selloff.
DAVIDsTEA Inc. (DTEA - Get Report) shares were up 6% ahead of the company's earnings release after Thursday's closing bell.
India Globalization Capital Inc. (IGCC - Get Report) jumped 4% on the CBD news.
Other stocks in the sector traded lower Thursday.
Aurora Cannabis Inc. (ACB - Get Report) shares fell more than than 6% after the company invested $10 million in High Tide, a Canadian cannabis retailer that Aurora says is "developing an expanding network across Canada of cannabis and cannabis accessory retail stores."
Shares of Tilray Inc. (TLRY) were down 10% despite the news that the California Public Employees' Retirement System, the biggest pension fund in the country, owned 1,617 shares of the Canadian cannabis company.
Canopy Growth Corp. (CGC) declined 3.4%, while Cronos Group Inc. (CRON) and Aphria Inc. (APHA) dropped 5.5% and 8%, respectively.
....nicht so toll
Der Kommentar von Ben wurde ignoriert. Um die Kommentare von Ben wieder zu sehen, klicken Sie folgenden Link:
Und nun eine positive Information.
Altria investiert 1,88 Mrd USD für 45% Anteil an Cronos!
Der Kommentar von Selector wurde ignoriert. Um die Kommentare von Selector wieder zu sehen, klicken Sie folgenden Link:
Anbei mal wieder etwas Neues von ACB:
Aurora Increases EU Footprint with Medical Cannabis Shipment to Luxembourg
Receives Import and Export licenses and Commences Shipment to Luxembourg Market
EDMONTON, Dec. 6, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the company, through its wholly owned subsidiary Aurora Europe GmbH, has been selected by the Luxembourg Health Ministry for the supply of medical cannabis to that country and an initial purchase order for approximately 20 kilograms has been received.
The Company has received all required authorizations (import and export licenses) and has commenced its first shipment of high-grade medical cannabis to Luxembourg's Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from a European government.
"To our knowledge, Aurora is the first medical cannabis producer selected by the Luxembourg Health Ministry to supply dried cannabis flower," said Neil Belot, Chief Global Business Development Officer. "This is a reflection of the trust we have earned with governments and regulators around the world. We look forward to supplying patients in need in what will be the 7th European Union member country where we have exported plants or products to help meet growing patient demand."
Maximilian Weinberg Head of Business Development Aurora Europe GmbH, added, "Working directly with governments provides patients all over Europe the assurance that the medical cannabis products they consume meet the highest quality and safety standards. We are proud to be a trusted partner for both wholesalers and governments throughout Europe, and look forward to further increasing our footprint in this important growth market in which we have substantial early mover advantage."
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 22 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.
In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Caution Concerning Forward-Looking Statements
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur and include, but are not limited to the variety of cannabis products that Aurora will supply to the adult use market.. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX, NYSE nor their Regulation Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.
For further information: For Media: Heather MacGregor, (416) 509-5416, email@example.com; For Investors: Marc Lakmaaker, (647) 269-5523, firstname.lastname@example.org; Rob Kelly, (647) 331-7228, email@example.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, (212) 896-1233 / (212) 896-1203, firstname.lastname@example.org / email@example.com
Copyright © 2018 Aurora Cannabis Inc, All rights reserved.
Our mailing address is:
1500 - 1199 W. Hastings St. Vancouver BC V6E 3T5
Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list
uff.....da kann man kaum durchblicken und nie weiss man sicher wer wirklich im Recht ist.
Hier ein Interview:
Aphria Report Is Not a Condemnation of Pot Sector, Short-Seller Grego Says
Bloomberg Markets: The Close
December 5th, 2018, 9:36 PM GMT+0100
Gabriel Grego, Quintessential Capital Management founder, explains why he is short Aphria Inc. He speaks with Bloomberg's Caroline Hyde and Scarlet Fu on "Bloomberg Markets: The Close." (Source: Bloomberg)
Aphria habe ich nicht - aber CRON hatte ein ähnliches Schicksal und Aurora ist ja auch nicht auf dem Höhenflug...ich weiss gar nicht ob es sich lohnt dem allen
@Ben - Du hast sicher noch einiges über APHRIA....ob Aurora auch noch Leichen im Keller hat?
Aphria to review LATAM acquisition in face of 'inaccurate' allegations by short sellers
MarketWatch•December 6, 2018
Shares of Aphria Inc. sank 8.4% in premarket trade Thursday, after the Canada-based cannabis company said it has appointed a special committee to review its LATAM Holdings Inc. acquisition, which was completed in September. The shares had plummeted 43% over the past two sessions, closing Tuesday at a 17-month low, after short seller Quintessential Capital Management said Aphria's recent C$280 million Latin America acquisitions raised "major red flags," as its research suggested they appeared largely worthless, an allegation Aphria denied by saying it "unequivocally" stands behind the LATAM deal. On Thursday, the company said it remained confident in the process leading to the acquisition. "However, in the face of inaccurate and misleading accusations by certain short-sellers, whose sole interest is in profiting from a decline in the Company's shares, it is undertaking a comprehensive review, led by a Special Committee of independent directors of these, and any other, allegations in the interest of protecting Aphria shareholders," Aphria said in a statement. The stock had dropped 72.3% over the past three months, while the ETFMG Alternative Harvest ETF has shed 18.2% and the S&P 500 has lost 6.2%.
SHARE SHARE SHARE REPOST GREAT FACTS
Aphria CEO fires back at short-sellers, vows 'our side of the story'
David George-Cosh, BNN Bloomberg
Aphria Inc. Chief Executive Officer Vic Neufeld is firing back at a short-sellers' report that has sent his company's shares into a tailspin, vowing to soon release more detailed information after the pot producer failed to ease investors' nerves with its initial response.
In a phone interview with BNN Bloomberg, Neufeld said Aphria will soon provide a detailed, line-by-line response to the report released by Hindenburg Research and Quintessential Capital Management (QCM) on Monday that alleges the Leamington, Ont.-based company acquired assets in Jamaica, Argentina and Colombia worth a total of about $280 million at “vastly inflated” prices in a transaction the short-sellers claim benefited a group of insiders.
"We need a complete rebuttal, not a piecemeal rebuttal. There’s lots of allegations of impropriety and we want our deck to speak on the facts," Neufeld said on Wednesday.
In their report, QCM and Hindenburg Research allege that the foreign companies Aphria acquired in Jamaica, Argentina and Colombia appear to be “largely worthless” and that there were "systematic attempts to hide the true nature of these transactions." Both QCM and Hindenburg have taken short positions in Aphria, meaning they stand to benefit if its stock falls......
Veröffentlichungen von professionellen Shortsellern, sind für mich Marktmanipulation auf höchstem Niveau. Sie lösen immer eine Verkaufspanik aus, auch wenn der Ansatz oft auch hanebüchen scheint. Wir kennen einige Beispiele für diese Praxis – Aurelius und Wirecard waren jüngst in Deutschland betroffen und nun hat es einen der “Big Five” in der Cannabis Branche erwischt. Aphria Inc (TSX/NYSE: APHA, WKN: A12HM0 / ISIN: CA03765K1049) wurde von Quintessential Capital Management gemeinsam mit Hindenburg Research in die Zange genommen. Die Veröffentlichung selbst scheint sehr gut recherchiert zu sein obwohl ich nicht meine Hand für sie ins Feuer legen werde. Sie sollten immer im Auge behalten, dass dieser Bericht einen Zweck verfolgt – der Kurs soll sinken! Je tiefer desto besser, denn umso mehr der Preis für die Aphira Aktie in die Knie geht umso mehr verdienen die Verfasser. Dieser “Skandal” färbt natürlich auf die gesamte Branche ab. Fast alle Cannabis Aktien mussten in den letzten Tagen mehr oder weniger Federn lassen außer der Cronos Group (TSX/NASDAQ: CRON, WKN: A2DMQY), die sich anscheinend mit dem Tabak Konzern Altria Group Inc. (NYSE: MO) in Gesprächen befinden. Für die “Marlboro News” war der Kursgewinn von 6% gestern eher gering.
Minus 50% - Was ist da los? Geht der Musterknabe den Bach runter? Wie geht es weiter? | wallstreet-online.de - Vollständiger Artikel unter:https://www.wallstreet-online.de/nachricht/11062775-minus-50-los-musterknabe-bach-runter-weiter
Hallo Petra, die Sache mit Aphria und dem gesamten Sektor ist spannend. Für Aphria sieht es nicht gut aus. Kannst du alles im wallstreet-online.de verfolgen.
Mal sehen, wie es weiter geht. Allgemein ist der Cann-Sektor überbewertet, was die Shorties zum Anlass nehmen um zu agieren. Heute soll nochmals eine Medienmitteilung von Hindenburg Research kommen, was Aphria angeht und angeblich hammermässig sein soll. Wer weiss, was da geschmiedet wird.
...gestern hoffte ich auf eine Erholung da die Amis weg waren. Das Gegenteil zB Aurora nochmals fast 13% runter. Möchte gerne wissen wer/was dahinter steckt. Meine ehemaligen Gewinne haben sich mehr als aufgelöst. Dennoch wird immer wieder zum Einstieg getrommelt.....
Pot Stock Plunges 30% After Short Seller Exposes "Elaborate Shell Game"
by Tyler Durden
Mon, 12/03/2018 - 15:01
It's been another volatile session for pot stocks broadly.
Day traders could be forgiven for feeling dazed and confused on Monday (for once, it may not have been due to overindulging in their favorite "commodity"). Shares of Tilray, Cronos and other pot stocks fluctuated between gains and losses - while shares of Aphria, another large Canadian pot stock plunged - following two scathing presentations from short sellers during a conference in New York City organized by famed short seller Whitney Tilson......
.....Rounding out the day's pot stock-related news, Reuters reported that Altria was in "early stage" talks to acquire Cronos Group, another Canadian pot producer, as it seeks to diversify its holdings.
Pot stocks have trended lower since Canada legalized recreational cannabis sales back in October. While the sector has largely suffered from a bubble-like influx of capital, concrete reports about a deal where an established beer or tobacco company buys a stake in a cannabis firm - like Constellation brands did with Canopy Growth - could send shares higher.
....da wird nur so rumgeschupst...
an hour ago
Marijuana Stocks Gaining Attention This Week (kann man wohl sagen - leider negative Attention)
The Horizons’ Marijuana Life Sciences ETF (HMMJ) (HMLSF) is currently the largest and most representative marijuana exchange traded fund on the markets. The ETF attempts to duplicate, to an extent, the performance of the North American Marijuana Index, which was created to reveal the performance of a group of North American Life Sciences companies which have a large focus of their business in the marijuana industry.
Since its initial trading date in April 2017, the marijuana ETF has yielded a return of about 46% and is still up nearly 30% over the last trailing year. For comparison, the SPDR S&P 500 ETF (SPY) gained about 15% during the same time period, while being up just 3.5% over the last year.
Horizons’ Marijuana Life Sciences ETF’s Holdings Include:
Click Here For Top Marijuana Stocks To Watch In December
Aphria: A Shell Game With A Cannabis Business On The Side
Dec. 3, 2018 8:40 AM ET
About: Aphria Inc. (APHA), Includes: BKDCF, MSRT, RIOT, SOLCF
Hindenburg Investment Research
Activist investor, value, long/short equity
Aphria’s recent C$280m Latin American acquisitions raise major red flags. Our extensive on-the-ground research shows that the transactions appear to be largely worthless.
Example: The official registered office of Aphria’s C$145m Jamaican acquisition is an abandoned building that was sold off by the bank earlier this year.
Example: Aphria’s C$50m Argentine acquisition publicly boasted sales of US$11m in 2017. A worker at the company, however, affirmed that 2017 revenue was only US$430k.
Documents show that Aphria insiders were likely undisclosed beneficiaries of the deals. We estimate Aphria has diverted upwards of C$700m via such transactions, or ~50% of Aphria’s total net assets.
Aphria consistently generates negative cash, and its cannabis seems to be of low quality. Interviews with sources describe facilities infested with bugs, stricken with mold, and having failed audit inspections.
Any time an exciting new industry draws widespread attention it also draws retail capital, which in turn can draw unscrupulous actors. This is not a story about the cannabis industry and its commercial potential, nor is it a story about valuations and competitive marketplace dynamics. This is simply about one of the larger companies in the industry that appears to have diverted a tremendous amount of money toward the private interests of its insiders at the direct expense of its public shareholders......
....jetzt haben sie dann bald alle durch mit unendlichen Shortverkäufen - als solche Papiere hoch gingen gab es öfter "halt", jetzt lässt man sie einfach
ins Bodenlose sausen - Börsenaufsicht scheint es nicht zu geben.
Canada’s struggle to supply legal weed described as ‘national shortage’ that could last months
Max A. Cherney
MarketWatch•November 27, 2018
....dann könnten die Papiere ja wieder mal steigen....
Thanx Ben - habe ich gleich an meine Tochter weitergeleitet.
Besten Dank für die eingestellten Infos!
Hier noch ein interessanter Artikel, der Frauen betrifft.
Cannabis tampons: Women say cramps disappear within 20 minutes
Cramps and lower back pain were all reportedly helped by the new, cannabis-infused products, say reviewers.
Hier mal wieder was von ACB:
Das fehlt hier wie ich sehe
BRIEF-Aurora Cannabis Reports Q1 Revenue Of $29.7 MLN VS $8.3 MLN
Nov 12 (Reuters) - Aurora Cannabis Inc :
* AURORA CANNABIS ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2019
* AURORA CANNABIS INC QTRLY REVENUE$29.7 MILLION VERSUS $8.3 MILLION
* AURORA CANNABIS INC QTRLY CASH COST OF SALES PER GRAM OF DRIED CANNABIS SOLD OF $1.90
* AURORA CANNABIS INC QTRLY GROSS MARGIN ON CANNABIS OF 70%, UP 12%
* AURORA CANNABIS - SEES AROUND YEAR END 2018 INTO BEGINNING OF CALENDAR 2019, CO WILL HAVE PRODUCTION RUN RATE IN EXCESS OF 150,000 KG PER ANNUM
* AURORA CANNABIS INC - EXPECTS TO SUBSEQUENTLY SCALE UP PRODUCTION RUN RATE TO OVER 500,000 KG PER ANNUM INTO CALENDAR 2019
* AURORA CANNABIS INC QTRLY NET INCOME $104.2 MILLION VERSUS $3.6 MILLION
Source text for Eikon: Further company coverage:
EDMONTON, Nov. 12, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX | NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM), announced today its financial and operational results for the first quarter ended September 30, 2018.
Q1 2019 Financial and Operational Highlights
In thousands ('000s) unless otherwise noted
Cannabis revenue (1)
Gross margin on cannabis sales (2)
General and administration expense
Sales and marketing expense
Earnings attributable to common shares
Cash cost of sales per gram of dried cannabis sold(3)
Cash cost to produce per gram of dried cannabis sold(3)
Active registered patients
Average net selling price of dried cannabis (4)
Average net selling price of cannabis extracts (4)
Cannabis revenue for Q1 2019 was comprised of revenues from both medical and adult-use markets (adult use revenues of $0.6 million reflect only Aurora's initial shipments received by provinces in final days of September 2018 and took place prior to Aurora Sky receiving its sales license on October 17, 2018). Q4 2018 and Q1 2018 cannabis revenues were comprised solely of revenues from medical cannabis
Represents the gross margin on cannabis sales before fair value adjustments
Represents the cash cost of sales and cost to produce per gram sold of dried cannabis produced by Aurora
Represents the average net selling price per gram of dried cannabis or per gram of dried cannabis equivalent.
Commencement of Sales to Canadian Adult Consumer Use Market
On October 17, 2018, sales of cannabis for adult consumer use in Canada, legalized through Bill C45, commenced. Aurora recorded a strong performance, ranking top or among the top selling products and brands in many of the provinces the Company committed to supplying, for the first two weeks to October 31, 2018.
Provincial Highlights (for the period up to October 31, 2018):
Q1 2019 Highlights:
"We continue to successfully execute our differentiated and diversified strategy committed towards domestic and international expansion in the medical cannabis market, adult consumer use sales, production scale-up, innovation, plant and medical research, and product development," said Terry Booth, CEO of Aurora. "The commencement of adult consumer use sales in Canada has been very successful for Aurora, with strong performance across all product categories and brands. Our initial roll-out success demonstrates how our high-quality Aurora Standard products and well-positioned brands have resonated strongly with the consumer market and our preparedness for the logistical challenges in effectively bringing our products to market. Given the strong unmet consumer demand evident across Canada, we are confident that our rapidly increasing production capacity will result in continued acceleration of revenue growth."
Mr. Booth added, "We also continue to perform well in our international medical business. With the acquisition of ICC Labs, which we expect to close in the coming weeks, we are establishing leadership in Latin America. In addition to ongoing international growth and expansion led by our team at Aurora Europe, we were also the first non-government organization to export medical cannabis to Poland, a medical market with a population roughly equal to Canada. Across our international activities, we have established significant early mover advantage and market leadership. With the scale-up of our domestic and international production facilities, we anticipate increased availability of product to service these developing markets which will drive further global growth for the Company."
Glen Ibbott, CFO, added, "In Q1 2019, we continued to propel Aurora's growth making critical investments in our corporate, sales, and marketing talent and capabilities. A significant portion of our Q1 2019 marketing spend was in preparation for the adult consumer use market with numerous branding and market awareness initiatives. With more restrictive marketing regulations in effect as of October 17th, we will see a significant reduction in average marketing spend over the remainder of the fiscal year. We also anticipate a reduction in other one-off expenditures, such as the integration costs related to the MedReleaf, CanniMed, and Anandia acquisitions."
Mr. Booth concluded, "As a science, medical and patient focused organization, we are committed to continue serving our patients with the products they require. As we built up inventory levels in anticipation of the adult consumer use market, we prioritized product availability for our over 67,000 existing patients. With production ramping up, we anticipate once again pro-actively driving additional growth in this core medical segment, both domestically and internationally."
Q1 2019 and Subsequent Operational Highlights
Facilities and Production update
During and subsequent to the quarter, the Company made significant progress towards increasing its production capacity, including receipt of various sales and production licenses. Based on grow rooms in production, the Company currently is running at an annualized run rate of 70,000 kg. Management anticipates that around calendar year end 2018 into the beginning of calendar 2019, Aurora will have a production run rate in excess of 150,000 kg per annum based on grow rooms in production, with subsequent scale up to over 500,000 kg per annum (excluding additional capacity through the acquisition of ICC Labs).
On October 17, 2018, the Company received its Health Canada sales license for Aurora Sky, allowing Aurora to increase product availability across Canada. Facility construction is now materially complete, including exterior structure, landscaping, commissioning, and harvest and waste rooms.
Aurora continues to populate additional bays at the facility, with all 17 rooms anticipated to be ready to receive plants within the coming month, and the facility fully planted around calendar year end, ramping up to full capacity. The recently planted rooms were populated using the successfully commissioned automation systems, which function as anticipated, resulting in substantially increased facility efficiencies as compared to traditional greenhouses or indoor grow facilities.
Aurora Sky is a technologically highly sophisticated facility, built to deliver exceptional operational efficiencies, including energy, water and nutrient use. In addition to harnessing the power of the sun through the use of highly specialized glass with strong light diffusing characteristics, the Company captures the excess heat generated in the facility during the day, storing it in the successfully commissioned heat sink to be reused when additional heat energy is required, usually during night time hours. The facility is also set up to harness the higher ambient temperatures during the warmer months to supply additional free heat, while the colder months provide free additional cooling capacity.
The electricity consumed by the facility is supplied through two independent sub-stations, which feed two independent electrical rings. The rings have interconnects, as well as a back-up independent power generator, to ensure full redundancy. Furthermore, the electrical rings are monitored and controlled by a digitalized management system with switch gear to move power through the facility quickly and efficiently.
The measures described above ensure a very significant reduction in energy use compared to more traditional facilities that yield a similar production output on an annual basis.
On July 30, 2018, the Company received a Health Canada dealer's license for its Mountain Facility in Cremona, Alberta. This license allows Aurora to expand research and product development activities with cannabinoids and their derivatives not covered under the Cannabis Act, as well as import and export cannabis products to and from international markets, subject to applicable regulations.
On September 28, 2018, Aurora Mountain also received its Health Canada production license to produce encapsulated oils. Aurora is producing unique, integral hard-shell capsules for the medical and adult consumer use markets.
The Company received its sales license for Aurora Vie in July 2018. The facility is now operating at full capacity, producing at a run rate of 4,000 kg per annum.
On August 22, 2018, the Company received Health Canada authorization to begin production of cannabis softgel capsules at its Aurora Vie facility in Pointe-Claire, Quebec. On October 17, 2018, the Company received its Health Canada softgel sales license. The Company utilizes technology it has exclusively licensed from strategic partner Capcium, in which Aurora has a strategic investment. High volume production of softgels at Vie has started, resulting in greater availability of this higher margin product.
On September 7, 2018, Aurora received a Health Canada production license for its Eau facility in Lachute, Quebec. Aurora Eau was purpose-built to EU GMP standards and represents the next evolution of Aurora's indoor-grow facilities, where novel and exotic strains will be grown for both the medical and adult consumer-use markets. Aurora Eau, which is fully planted with first harvest anticipated shortly, was officially opened on November 5, 2018.
Aurora Nordic, Phase I and II
On August 13, 2018, the Company successfully shipped cultivars from Aurora Mountain to Odense, Denmark to commence populating the Aurora Nordic Phase I facility, named "Base One". The facility is ramping up to its full 8,000 kg per annum capacity, increasing product availability for the EU markets. The Company has commenced with a 54,000 square feet expansion of Base One, anticipated to be fully completed towards the end of the first calendar quarter of 2019. Pharma-grade processing equipment will be moved into the facility, with completion and full commission anticipated for early 2019.
Construction of Aurora Nordic Phase II, named "Nordic Sky", has commenced with site preparation, ground and drainage work.
On August 13, 2018, Aurora, through its wholly-owned subsidiary MedReleaf, received EU GMP certification on its facility in Markham, Ontario. This certification will allow MedReleaf Markham to access rapidly growing, higher margin, heavily regulated EU markets.
On September 7, 2018, the Company, through its wholly-owned subsidiary MedReleaf, received its Health Canada oils production license for its facility located in Bradford, Ontario. This license allows MedReleaf Bradford, a 210,000 square foot facility which features a high-volume CO2 extraction facility, to significantly increase the production of oils in fiscal 2019. MedReleaf Bradford continues to produce oils, a higher-margin product, in anticipation of the receipt of its oils sales license.
To date, Bradford has completed 13 cultivation rooms, 5 drying rooms, 2 trim rooms, an extraction room, packaging area and the vault. Two additional grow rooms were recently commissioned with only two grow rooms remaining to be licensed.
On April 16, 2018, the Company acquired approximately 71 acres of land in Medicine Hat, Alberta, for the construction of "Aurora Sun", a 1.2 million square foot, highly automated cannabis production facility with ultra-low operating costs. Construction of Aurora Sun is on schedule with site preparation, backfilling, and 80% of pilings completed to date. Aurora expects to commence erecting the buildings metal frame in the beginning of calendar year 2019. Near completion of the piling work is a major milestone as it ensures greater efficiency of construction work during the winter months.
On July 3, 2018, the Company, through its wholly-owned subsidiary, CanniMed, received Health Canada authorization to commence sales of CanniMed capsules, a line of vegan capsules which became available to patients on August 22, 2018. Facility upgrades are continuing, and increased yields and efficiencies are already being realized.
The Company is successfully executing on a comprehensive innovation strategy that covers the entire cannabis industry value chain from breeding and genetics, through facility development to medical research product development and post production analytics. Objective of the innovation strategy is to yield industry leading operational efficiencies, as well as the development of a broad portfolio of high-margin, targeted medical and consumer use products.
Aurora has been executing successfully on developing a fully vertically integrated company. This strategy combines both organic initiatives and M&A. To date the Company has completed over 25 transactions (acquisitions and strategic investments), covering the entire spectrum of the cannabis industry value chain. Consequently, Aurora has been successful in establishing leadership across its activities and is exceptionally well positioned to capitalize on its early mover advantage globally, across its medical, wellness, and adult consumer use market segments.
To date, ACI's management, board, and advisory teams have completed the following strategic investments and financing activities:
The Wagner Dimas technology has now been installed at Aurora, and the large-scale production of pre-rolled product has commenced in order to fulfill orders received from provincial buyers who have begun supplying the Canadian adult-use market.
Financing and Capital Market Activities
The Company has the option to upsize the facility to $250 million, subject to certain conditions. The debt facility is primarily secured by Aurora's production facilities and can be repaid without penalty at Aurora's discretion.
Financial Review Q1 2019
The Company primarily operates in the cannabis market which includes auxiliary support functions such as CanvasRX patient counselling services; ALPS design, engineering and construction services; and cannabis analytical product testing services through the Company's recent acquisition, Anandia Laboratories Inc. ("Anandia"). With the Cannabis Act effected as of October 17, 2018, Aurora made its first shipments to provinces across Canada at the end of September 2018.
In thousands ('000s)
Cannabis segment revenue
Canadian dried cannabis
Canadian cannabis extracts (1)
European dried cannabis
Total medical cannabis revenue
Adult-use cannabis revenue
Design, engineering and constructions services
Patient counselling services
Analytical testing services
Total cannabis segment revenue
Other segment revenues
Cannabis extracts revenue includes cannabis oil revenue and cannabis capsule revenue in Q1 2019. Cannabis extracts revenue for Q4 2018 and Q1 2018 comprised solely of cannabis oil revenue.
In the first quarter of 2019 ("Q1 2019") total medical cannabis revenue grew to $24.0 million, a 62% increase compared to the fourth quarter of 2018 ("Q4 2018") and a 229% increase compared to the first quarter of 2018 ("Q1 2018"). With the Cannabis Act in effect as of October 17, 2018, the Company completed its first shipments to Canadian provincial wholesalers of the adult-use market just prior to the end of the current quarter and recorded $0.6 million in adult-use cannabis sales.
Total revenue grew to $29.7 million in Q1 2019, representing a 55% increase compared to Q4 2018 and a 260% increase compared to Q1 2018. Revenue growth compared to the same quarter in the prior year was attributable mainly to higher patient numbers following the acquisition of CanniMed and MedReleaf, increased product availability through scale up of operations from the CanniMed and MedReleaf acquisitions, an increase in the average net selling price of dried cannabis, development of international markets, the commencement of the Canadian adult-use market, and product diversification.
The average net selling price of cannabis sold was $9.19 per gram in Q1 2019, consistent with Q4 2018, and a 12% increase compared to Q1 2018 as a result of an increase in cannabis extracts sold. Total product sold was 2,676 kilograms of dried cannabis and cannabis extracts in Q1 2019, an increase of 65% as compared to Q4 2018, and 201% compared to Q1 2018.
Total cannabis inventory and biological assets increased 97% to $80.8 million in Q1 2019 compared to Q4 2018 as Aurora chose to constrain international sales in order to continue servicing the Canadian medical market, while building inventory in preparation for the Canadian adult consumer-use market. The increase reflects the addition of MedReleaf's inventory and biological assets and Aurora's efforts to bolster its inventory levels to serve the medical markets and prepare for the high demand of the Canadian adult consumer-use market.
Cost of sales
Cash cost of sales per gram of dried cannabis sold increased by $0.03 to $1.90 in Q1 2019 as compared to the prior quarter (Q4 2018), mainly due to higher packaging costs from the inclusion of MedReleaf's results and increased overall packaging costs of the Company resulting from stringent regulatory requirements of the Cannabis Act. Cash cost to produce per gram of dried cannabis sold decreased by $0.25, or 15%, to $1.45 in Q1 2019 as compared to Q4 2018, and by 22% as compared to Q1 2018, mostly due to integration of Aurora's yield expertise at CanniMed facilities. Production costs per gram are expected to decrease significantly once Aurora Sky is fully operational and the efficiencies from automation, scale and yield expertise are realized at all Aurora facilities.
Q1 2019 gross profit was $8.1 million, compared to a $20.6 million in Q4 2018. The change in gross profit during the period was partially attributable to higher sales of inventory and lower fair value gains on changes in biological assets, which were partially offset by higher gross profits before fair value adjustments.
Aurora continues to make significant investments in its infrastructure and skilled talent, scaling the organization to better realize the tremendous opportunities ahead in the global medical cannabis markets and the Canadian adult consumer-use market.
As a result, general and administration costs ("G&A") increased to $35.9 million in Q1 2019, compared to $22.6 million in Q4 2018. Sales and marketing costs (S&M) in Q1 2019 increased to $29.4 million dollars, from $14.8 million in Q4 2018, mainly as a result of certain one-time activities and programs specifically for the period leading up to the October 17, 2018 Cannabis Act effective date in Canada. The integration of CanniMed accounted for 17% of the increase to G&A and 12% of the increase to S&M.
Q1 2019 net income increased to $104.2 million, compared to a net income of $79.3 million in Q4 2018 and $3.6 millionin Q1 2018. The increase was primarily attributable to the unrealized non-cash gain on derivatives and marketable securities, which was partially offset by increased finance costs, share-based payments, acquisition and project evaluation costs.
Cash Position, Cash Flows, and Working Capital
Net cash and cash equivalents on hand increased from $89.2 million at the end of Q4 2018 to $147.8 million as at Q1 2019. Working capital at the end of Q1 2019 was $548.4 million, as compared to $144.5 million at the end of Q4 2018. The change in working capital was largely attributable to an adjustment to the Company's investment in The Green Organic Dutchman ("TGOD"), which was previously treated as an investment in associate and was reported at cost; the investment is now treated as a marketable security and reported at fair value. The inclusion of MedReleaf's balances accounted for $57.6 million in additional working capital.
The Company also has strategic investments in a number of publicly-traded companies. Based on the closing prices at November 9, 2018, the value of the common shares and "in-the-money" warrants held by the Company was $407.57 million.
The Company anticipates that it has sufficient liquidity and capital resources to meet all of its currently planned expenditures for at least the next twelve months.
For the three months ended June 30, 2018, pro-forma revenue, including the results of MedReleaf, Anandia Labs, and Agropro/Borela, would have been $35.8 million.
Aurora is exceptionally well‑positioned in all of its active markets, including adult consumer-use market, Canadian medical and the international medical markets, with compelling brands, a broad and expanding product portfolio, and strong patient and consumer recognition.
In fiscal 2019, the Company will continue to focus on expanding capacity and sales growth in all its markets, in addition to exploiting further product development and innovation, medical research, continued international expansion and realization of acquisition synergies.
Aurora is rapidly accelerating production out of its newly licensed facilities, starting with Aurora Sky, which is expected to ramp to full 100,000 kg per annum capacity over the coming months. The Company anticipates reaching a production run rate of approximately 150,000 kg per annum early in calendar 2019, scaling up subsequently to over 500,000 kg per annum (excluding additional capacity through the pending ICC Labs acquisition) through further "Sky Class" facilities, Aurora Sun and Aurora Nordic. The high degree of automation, and customized and fully controlled growing conditions at the Sky Class facilities are anticipated to result in production costs well below one dollar per gram. Management believes these factors together will deliver high growth and continuously improving margins.
While the historic milestone of Canada becoming the first G7 nation to legalize the adult consumer-use market creates a very significant growth opportunity, the Company maintains its position that long term the international medical market has the most significant growth prospects, and is expected to grow to 10 million kilograms per annum according to industry observers. The Company has established significant early mover advantage, has a presence on five continents, and is currently Europe's largest distributor of medical cannabis. Aurora also currently owns two of the seven cannabis production facilities in the world that are EU GMP certified, and additionally owns one EU GMP certified distribution facility in Germany, ensuring continued access to restrictive markets. Management believes this early mover advantage, coupled with the strength of its growing international management teams, will enable the Company to continue expanding its significant market share in the global medical market.
The Company granted a total of 250,000 options to purchase common shares of Aurora to Officers of the Company. The options vest annually over 36 months and are exercisable at $9.94 per common share.
Aurora will host a conference call today, November 12, 2018, to discuss these results. Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley, Chief Corporate Officer, will host the call starting at 10:30 a.m. Eastern time. A question and answer session will follow management's presentation.
Monday, November 12th, 2018
10:30 a.m. Eastern Time | 8:30 a.m. Mountain Time
(416) 849-0833 or (855) 859-2056
Available until 12:00 midnight Eastern Time Monday November 19, 2018
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 19 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).
For more information about Aurora, please visit our investor website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.,
Forward looking statements
Neither TSX nor NYSE, nor their Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange and the New York Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
For further information: For Media: Heather MacGregor, +1.416.509.5416, firstname.lastname@example.org; For Investors: Marc Lakmaaker, +1.647.269.5523, email@example.com; Rob Kelly: +1.647.331.7228, firstname.lastname@example.org; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, Phone: (212) 896-1233 / (212) 896-1203, Email: email@example.com / firstname.lastname@example.org
EX-99.1 2 ex991.htm NEWS RELEASE DATED NOVEMBER 22, 2018
Aurora Cannabis Receives Final Regulatory Approval and Completes Acquisition of ICC Labs
Establishes Leadership Position and Platform for Growth in Latin American Market
TSX | NYSE: ACB
EDMONTON, Nov. 22, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or "the Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and ICC Labs Inc. (TSX-V: ICC) ("ICC") are pleased to announce today the completion of the previously announced plan of arrangement (the "Arrangement") pursuant to which Aurora has acquired all of the issued and outstanding common shares of ICC for $1.95 per share (payable in common shares of Aurora (the "Aurora Shares")), reflecting an aggregate purchase price of approximately $290 million. ICC is now a wholly-owned subsidiary of Aurora. Completion of the Arrangement follows receipt of approval of the Arrangement from the Instituto de Regulación y Control del Cannabis, the Uruguayan regulatory authority overseeing the regulation and control of cannabis in Uruguay.
ICC's common shares will be delisted from the TSX Venture Exchange (the "TSX-V"), subject to TSX-V approval, and applications will be made for ICC to cease being a reporting issuer.
The acquisition of ICC establishes Aurora as the industry leader in Latin American, a region which encompasses more than 650 million people from across Mexico, the Caribbean, Central America, and South America. ICC, based in Uruguay, the first country in the world to legalize cannabis for adult consumer use, has developed a strong portfolio of high-quality, low-cost production assets, product offerings, and commercial agreements. Located in Uruguay's free trade zone, ICC's state-of-the-art science and GMP compliant processing facility, the first of its kind in Latin America, brings very significant capacity and early mover advantage to build significant market share both in Latin America and the international cannabis and wellness markets.
"This transaction combines two pioneering cannabis companies with fully aligned international growth ambitions, immediately positioning Aurora as the market leader in Latin America, an area with well over 650 million people," said Terry Booth, CEO of Aurora. "Not only does ICC have substantial low cost, high-quality production capacity, it is the first company in Latin America which has completed a GMP compliant extraction facility, which will play an important role in supplying higher-margin CBD-based products for the global cannabis and wellness markets. Together, ICC and Aurora will accelerate the development of our well-diversified product portfolio, and extensive distribution channels to capitalize on the substantial opportunities in the global cannabis industry."
Neil Belot, Chief Global Business Development Officer, added "Alejandro and his team have developed one of the deepest international networks Aurora has encountered. ICC has leveraged its early mover advantage in Uruguay to capitalize on significant growth opportunities in the broader Latin American cannabis markets. With world-class production, process facilities and distribution infrastructure in place, this transaction strengthens Aurora's position as the global partner of choice in multiple international markets."
Alejandro Antalich, CEO of ICC Labs added, "The complementary nature of our two organizations makes this transaction an ideal fit that will allow us both to realize our ambitious growth strategies. We're excited to announce our upcoming official grand opening of the first state-of-the-art laboratory in Latin America on November 28th. This facility based in Uruguay is focused on the development of pharmaceutical grade products derived from cannabis and hemp. With our Latin American facilities coming online, as well as multiple supply and distribution agreements in large international markets in place, we believe that Aurora's resources, innovation capabilities, and broad global distribution networks represent an ideal partner to accelerate our growth."
ICC brings to Aurora, among other strategic synergies, the following competitive advantages.
Significant, Low-cost Capacity
Strong Foundation to Capitalize on the Significant Global CBD Wellness Market Opportunity
Science, High-margin Products and Strong Genetics
Full details of the Arrangement and certain other matters are set out in the management information circular of ICC dated October 3, 2018 (as updated by the news release of ICC dated October 15, 2018) (the "ICC Circular"). A copy of the ICC Circular and other meeting materials can be found under ICC's profile on SEDAR at www.sedar.com.
Under the Arrangement, each holder of common shares of ICC ("ICC Shareholder") has received approximately 0.2161 Aurora Shares for each common share of ICC held and Aurora has issued a total of 31,904,668 Aurora Shares pursuant to the Arrangement (not giving effect to the exercise of any ICC Compensation Options or ICC Warrants, as such terms are defined in the arrangement agreement dated September 8, 2018 between ICC and Aurora), which as of November 21, 2018 represented approximately 3.20% of the outstanding Aurora Shares after giving effect to the Transaction.
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 20 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
For more information about Aurora, please visit our investor website, investor.auroramj.com
ICC is a fully licensed producer and distributor of medicinal cannabinoid extracts, adult usage cannabis and industrial hemp products in Uruguay as well as a fully licensed producer of medicinal cannabis in Colombia. ICC has active operations in Uruguay, and is focused on becoming a worldwide leading producer of cannabinoid extracts, giving support and promoting responsible use for medicinal purposes, backed by scientific research and innovation, while following strict compliance with standards for quality and safety.
Neither the TSX, NYSE, TSX-V nor their Regulation Services Provider (as that term is defined in the policies of the TSX, NYSE, and TSX-V) accepts responsibility for the adequacy or accuracy of this release.
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to statements with respect to: results of operations, anticipated benefits and cost synergies associated with the Transaction, internal expectations, estimated margins, expectations for future growing capacity, costs and opportunities, the effect of the Transaction on the combined company and its future strategy, plans, objectives, goals, targets and future developments, the completion of any capital projects or expansions, the anticipated timing for the de-listing of ICC from the TSX-V and for ICC to cease to be a reporting issuer and the expected benefits of the Arrangement.
ICC Shareholders are urged to carefully read the management information circular of ICC dated October 3, 2018 (as updated by the news release of ICC dated October 15, 2018) and related materials in their entirety as they contain important information regarding the Arrangement and its consequences to ICC Shareholders.
Forward-looking statements are based on the opinions and estimates of management of ICC and Aurora at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statement, whether expressed or implied, including, without limitation: inability to realize anticipated synergies; future legislative and regulatory developments involving cannabis; the cannabis industry in Canada and elsewhere generally; income tax and regulatory matters; the ability of ICC and Aurora to implement their business strategies; competition; crop failure; currency and interest rate fluctuations; failure to realize the expected benefits of the Arrangement; compliance with all applicable laws and other customary risks associated with transactions of this nature; and general economic conditions. Forward-looking statements should be considered carefully and undue reliance should not be placed on them.
Management of Aurora and ICC provide forward-looking statements because they believe they provide useful information to readers when considering their investment objectives and cautions readers that the information may not be appropriate for other purposes. Consequently, all of the forward-looking statements made in this news release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, ICC and Aurora. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management of Aurora and ICC at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
These forward-looking statements are made as of the date of this news release and each of ICC and Aurora assume no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as expressly required by applicable law.
ICC Labs Inc. (CNW Group/Aurora Cannabis Inc.)
View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-receives-final-r...
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2018/22/c7061.html
For further information: For Media: Heather MacGregor, (416) 509-5416, email@example.com; For Investors: Marc Lakmaaker, (647) 269-5523, firstname.lastname@example.org; Rob Kelly, (647) 331-7228, email@example.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, (212) 896-1233 / (212) 896-1203, firstname.lastname@example.org / email@example.com; For ICC: Alejandro Antalich, CEO, (598) 2900-0000 ext. 404, firstname.lastname@example.org
CO: Aurora Cannabis Inc.
CNW 17:58e 22-NOV-18
Canada's Top 7 Marijuana Growers Lost Nearly $300 Million This Quarter
Sean Williams, The Motley Fool
Motley Fool•November 20, 2018
There's no denying that the marijuana industry is growing like a weed. The legalization of recreational marijuana in Canada is big news, and it clearly puts the cannabis industry on the map as a high-growth and viable business model. According to various Wall Street estimates, the legal industry in Canada could see around $5 billion in added annual sales from adult-use pot within a matter of years.
Of course, the expectation of rapid sales growth and (eventual) strong profitability has sent nearly all marijuana stocks soaring. The question is, with recreational cannabis now legal in our neighbor to the north: "Can these pot stocks live up to expectations when it comes time to report their operating results?"
Following earnings releases from all seven of the projected top producers over the last month, the early indication isn't very encouraging.
A rundown of Canada's projected top cannabis producers
As a brief rundown, here are the marijuana stocks expected to lead in annual weed output once at full capacity:
Brand-name growers lost a lot of money in their recently ended quarters.....
Pot stocks: Still 'better at growing their bank accounts than growing cannabis'
3:40 PM ET Wed, 14 Nov 2018
Cannabis companies Tilray, Canopy Growth and Aurora Cannabis all took big stock hits after earnings losses outweighed revenue growth. While demand is high, marijuana growers are struggling to increase supply, and long-term investors should be wary....
Citron Still Short Tilray, Notes Canopy Growth Is The 'Global Leader' In Cannabis
Benzinga•November 12, 2018
Tilray Inc (NASDAQ: TLRY)'s stock is up another 12.5 percent in the past week, but Citron Research’s Andrew Left said he's still short the stock and Canadian marijuana companies will not be the winners from a potential U.S. marijuana legalization.
At the Reuters Global Investment Outlook Summit on Monday, Left said leading Canadian marijuana companies would likely get steamrolled by larger American competitors in the event of U.S. legalization given that there is no brand value or competitive moat in the U.S. cannabis business.
“When U.S. LPs (companies) go public in the next few years it will make these Canadian companies laughable,” Left said.
Why It’s Important
Tilray shares are now up 339 percent in the past three months, and the U.S.-listed Canadian cannabis company isn't alone:
Canadian marijuana stocks have capitalized on investor enthusiasm following nationwide recreational cannabis legalization in Canada in October and state legalization measures approved by U.S. voters last week in Michigan and Missouri.
Left said he understands why investors are excited about the cannabis market but said Tilray is a dangerous way to play the trend. Right now, Left said Canopy Growth is the global market leader, although he has no position in the stock....
.....dieser Citron-Left fällt hoffentlich mal ordentlich auf die Nase mit seiner ewigen Shorterei
CC Pharma verstärkt mit Aphria sein Importgeschäft und steigt in medizinischen Cannabismarkt ein.
Apotheken können ab sofort drei medizinische Cannabisprodukte bestellen.
Zum heutigen grausam roten Can-Tag, ein erfreulich, netter Lesestoff.
Aphria übernimmt CC Pharma und stärkt den Markt für medizinischen Cannabis in Deutschland
Nachrichten bereitgestellt von
Akquisition fügt neue vertikale und strategische Operationen in wichtigen Regionen der globalen Wachstumsstrategie hinzu
LEAMINGTON, ON, 8. November 2018 / CNW / - Aphria Inc. ("Aphria" oder das "Unternehmen") (TSX: APHA und NYSE: APHA) gab heute die geplante Übernahme der CC Pharma GmbH ("CC Pharma") bekannt. ist ein führender Distributor von pharmazeutischen Produkten an mehr als 13.000 Apotheken in Deutschland. Wenn die Transaktion abgeschlossen ist, wird sie die durchgängigen medizinischen Cannabisaktivitäten und -infrastrukturen des Unternehmens in Deutschland stärken, einem wichtigen Markt für die internationale Expansion von Aphria. Es wird erwartet, dass die Transaktion im Januar 2019 abgeschlossen wird.
"Diese Akquisition stärkt unsere Position in Deutschland, einem der gefragtesten Märkte für medizinisches Cannabis der Welt", sagte Vic Neufeld, CEO von Aphria. "CC Pharma ist Cashflow-positiv und verfügt über beträchtliche Erfahrung mit regulatorischen Anforderungen und internationaler Logistik. Es wird eine starke Ergänzung der Präsenz von Aphria in Deutschland sein, die einen tieferen Zugang zum wichtigen Apothekerkanal ermöglicht und unsere ehrgeizige globale Wachstumsstrategie vorantreibt."
CC Pharma wurde 1999 gegründet und ist ein führender Importeur und Distributor von EU-Arzneimitteln für den deutschen Markt mit einem Jahresumsatz von über 200 Millionen Euro. Über seine Tochtergesellschaft Aphria International hat Aphria zuvor einen Liefervertrag mit CC Pharma über den Export von rund 1.200 Kilogramm medizinischer Cannabisprodukte aus Kanada nach Deutschland angekündigt. Mit der Erfahrung von Aphria als weltweiter Cannabisführer wird das Unternehmen eine neue Abteilung von CC Pharma schaffen, die sich auf medizinisches Cannabis konzentriert. CC Pharma betreibt am Hauptsitz in Densborn eine Produktions-, Umverpackungs- und Etikettieranlage.
"Wir freuen uns, mit einem führenden globalen Cannabis-Unternehmen zusammenzuarbeiten, dessen Engagement für Qualität, Sicherheit und Patientenpflege eng mit unserem eigenen übereinstimmt. Dies ist eine aufregende Gelegenheit, auf unserem etablierten Netzwerk aufzubauen und unsere Teilnahme an einem schnell wachsenden, aufstrebenden Unternehmen zu fördern Industrie ", sagte Dr. Manfred Ziegler, Geschäftsführer von CC Pharma.
Die Transaktion wird die wachsende Präsenz von Aphria in Deutschland unterstützen, die einen dreigliedrigen Ansatz umfasst, der Nachfrage, Angebot und Vertrieb abdeckt. Anfang des Jahres hatte das Unternehmen über seine 100% ige Tochtergesellschaft Aphria Deutschland ("Aphria Deutschland") eine Beteiligung von 25,1 Prozent am Berliner Schöneberg-Krankenhaus erworben, die sowohl Ärzten als auch Patienten den Zugang zur medizinischen Aufklärung ermöglichte Cannabinoide. Dies war auch der erste Schritt in den Plänen von Aphria Germany, Schmerzbehandlungszentren in ganz Deutschland zu bauen und zu betreiben.
Um eine konstante Lieferung von importiertem Cannabis für deutsche Patienten sicherzustellen, baut das Unternehmen in Bad Bramstedt, Norddeutschland, eines der größten GMP-zertifizierten Cannabis-Gewölbe mit einem Fassungsvermögen von 5.000 Kilogramm. Um sich auf den Anbau im Land in Deutschland vorzubereiten, plant Aphria den Bau einer Forschungs- und Entwicklungszuchtanlage in Neumünster, Deutschland.
"Wir sind darauf fokussiert, auf dem medizinischen Cannabis-Markt in Deutschland eine Vorreiterrolle einzunehmen", sagte Hendrik Knopp, Geschäftsführer von Aphria Germany. "Durch die Kombination der Expertise von Aphria mit der etablierten lokalen Marktpräsenz von CC Pharma sind wir gut positioniert, um diese Reise fortzusetzen."
Aphria zahlt zum Abschluss Closing an CC Pharma in Höhe von 24,5 Mio. €. Nach Abschluß wird ein Earn-Out-Multiplikator für das zukünftige EBITDA von weiteren 23,5 Mio. € erzielt, wenn bestimmte Erfolgsziele erreicht werden.
Wir haben eine gute Sache, die wächst
Aphria ist ein weltweit führendes Cannabis-Unternehmen, das sich durch ein unerbittliches Engagement für unsere Mitarbeiter, Produktqualität und Innovation auszeichnet. Aphria hat seinen Hauptsitz in Leamington, Ontario - der Gewächshaushauptstadt Kanadas - und setzt Maßstäbe für die kostengünstige Produktion von sicherem, sauberem und reinem Cannabis in pharmazeutischer Qualität, der unter möglichst natürlichen Bedingungen angebaut wird. Aphria konzentriert sich auf ungenutzte Möglichkeiten und wird durch die neuesten Technologien unterstützt. Das Unternehmen setzt sich dafür ein, bahnbrechende Innovationen auf den globalen Cannabis-Markt zu bringen. Das Markenportfolio des Unternehmens stützt sich auf fachkundig recherchierte Erkenntnisse der Verbraucher, die auf die Bedürfnisse jedes Verbrauchersegments abgestimmt sind. Aphria basiert auf der generationenübergreifenden Expertise unserer Gründer in der kommerziellen Landwirtschaft. Durch einen diversifizierten Ansatz für Innovation, strategische Partnerschaften und globale Expansion mit einer Präsenz in mehr als 10 Ländern auf 5 Kontinenten wird ein nachhaltiger langfristiger Unternehmenswert erzielt.
Weitere Informationen finden Sie unter: aphria.ca
VORSICHTSMASSNAHMEN ZUR ZUKUNFTSWEISENEN AUSSAGEN: Bestimmte Informationen in dieser Pressemitteilung sind zukunftsgerichtete Aussagen im Rahmen der geltenden Wertpapiergesetze. Alle in dieser Pressemitteilung enthaltenen Aussagen, die keine historischen Tatsachen darstellen
Über Google ÜbersetzerCommunityMobilÜber GoogleDatenschutzerklärung & NutzungsbedingungenHilfeFeed
D. T. feuert Justizminister Session. Jetzt wird‘s interessant, wer wird sein Nachfolger/Nachfolgerin und welche Einstellung hat er oder sie zu dieser Sache.
Erfreulich war der Anstieg der Kurse!
PriceNov 7Nov 2600650700
Marihuana-Aktien steigen nach Sessions-Rücktritt massiv
Dem US-Justizminister war Cannabis ein Dorn im Auge. Sein Abgang war daher in der Branche unmittelbar spürbar, einige Aktien legten gar um über 30 Prozent zu. Mehr...
...ich frage mich schon warum alle wie auf Befehl runtergehen - das passiert regelmässig und ich finde das
mehr als ärgerlich. Börsenaufsicht scheint es nicht zu geben.
Auch ACB ist dabei mit kleiner Verzögerung - darum (noch) nicht auf dem Anhang.
Erfreulich ist es stieg anschliessend wieder
VALUATION BASED ON PRICE TO SALE RATIO
posted November 01, 2018 12:27 am by INVEST4LONG
i know Mj sector doesnt follow fundamentals at this moment but eventually it will may be next year or 2020- who knows. so compared the price to sale ratio of few companies : lower the latio is better...read more
so compared the price to sale ratio of few companies : lower the latio is better .
keep that in mind whole Sector's median is 4.2 - so more closer to sector median means less risk buy buying that company.
Source morning star:
yes there are some companies who is having less P/S ratio but i wanted to compare with some big names...
Read more at http://www.stockhouse.com/companies/bullboard#HKSOOf1RWIcwfzMk.99
....das steht in dem Namaste-Forum -
Ben hat am 30.10.2018 17:57 geschrieben:
Hier nochmals eine Einschätzung vom 29.10.2018/ siehe Video
Aphria wird ab dem 2. November 18 an der NYSE gehandelt. Kann man nur hoffen, dass sie einen besseren Start haben werden als. ACB.
Heute hat ja schon mal die Farbe im Can-Sektor von Rot nach Grün gewechselt.
Ist schon irre was hier so an Volatilität abgeht. Puh, da brauchst Geduld.
Hier nochmals eine Einschätzung vom 29.10.2018/ siehe Video
Aphria wird ab dem 2. November 18 an der NYSE gehandelt. Kann man nur hoffen, dass sie einen besseren Start haben werden als. ACB.
Heute hat ja schon mal die Farbe im Can-Sektor von Rot nach Grün gewechselt.
Ist schon irre was hier so an Volatilität abgeht. Puh, da brauchst Geduld.
Aphria hat schon mal tüchtig vorgelegt - fast 18% im plus - super!
....Deine Antwort war plötzlich weg ???
......A 'Repositioning' In Marijuana Stocks
Marijuana stocks reached nosebleed levels this summer and crashed after recreational legalization began in Canada. They continued to sell off Monday.
Curaleaf sank 27% on the Canadian Securities Exchange. Among U.S.-listed marijuana stocks, Canopy Growth (CGC) tumbled 14.55% in the stock market today, Cronos Group (CRON) lost 12.6%, Tilray (TLRY) fell 16%, and Aurora Cannabis (ACB) sold off 16%. Those companies all do business in Canada.
Curaleaf Executive Chairman Boris Jordan in an interview last week attributed the retreat in marijuana stocks, in part, to 'selling the news' and the broader market sell-off — a product of concerns about trade friction and higher borrowing costs. But he also said that a "repositioning" was occurring in marijuana stocks.
More cannabis investors, Jordan said, are pulling back from of the Canadian market. That market, he said, was overvalued and had limited growth potential due partly to Canada's population size.
"One, the U.S. market is bigger, so the growth potential's much more," he said. "Two, the stocks are a lot cheaper than the Canadian stocks. So I think that there is a relative repositioning taking place, because there are a lot of deals in the pipeline.".....
hmmmm.....tönt nicht sehr gut leider
Ich habe mir das NYSE -Opening auch anders vorgestellt.
Aber derzeit ist die allgemeine Marktsituation auch keine gute. Mal sehen, wie es weiter geht.
Bloomberg • Wed 4:51 PM
Cannabis Short Sellers Made Over $450 Million in Two Days
Marijuana stocks fall in worst-ever day for the sector
© 1998-2020 / cash
| Impressum |